SG10202013032YA - Phosphoramidates for the treatment of hepatitis b virus - Google Patents
Phosphoramidates for the treatment of hepatitis b virusInfo
- Publication number
- SG10202013032YA SG10202013032YA SG10202013032YA SG10202013032YA SG10202013032YA SG 10202013032Y A SG10202013032Y A SG 10202013032YA SG 10202013032Y A SG10202013032Y A SG 10202013032YA SG 10202013032Y A SG10202013032Y A SG 10202013032YA SG 10202013032Y A SG10202013032Y A SG 10202013032YA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphoramidates
- hepatitis
- virus
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462091686P | 2014-12-15 | 2014-12-15 | |
| US201462094117P | 2014-12-19 | 2014-12-19 | |
| US201562201974P | 2015-08-06 | 2015-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202013032YA true SG10202013032YA (en) | 2021-02-25 |
Family
ID=56127817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704785RA SG11201704785RA (en) | 2014-12-15 | 2015-12-07 | Phosphoramidates for the treatment of hepatitis b virus |
| SG10202013032YA SG10202013032YA (en) | 2014-12-15 | 2015-12-07 | Phosphoramidates for the treatment of hepatitis b virus |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704785RA SG11201704785RA (en) | 2014-12-15 | 2015-12-07 | Phosphoramidates for the treatment of hepatitis b virus |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10683319B2 (en) |
| EP (1) | EP3233878A4 (en) |
| JP (3) | JP6735751B2 (en) |
| KR (1) | KR20170110591A (en) |
| CN (1) | CN107428792B (en) |
| AU (2) | AU2015363042B2 (en) |
| BR (1) | BR112017012859A2 (en) |
| CA (1) | CA2969372C (en) |
| HK (1) | HK1244812A1 (en) |
| IL (2) | IL280459B2 (en) |
| PH (1) | PH12017550022A1 (en) |
| SG (2) | SG11201704785RA (en) |
| WO (1) | WO2016099982A2 (en) |
| ZA (2) | ZA201704104B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3043803B1 (en) * | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| US11311545B2 (en) | 2014-10-09 | 2022-04-26 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| BR112017012859A2 (en) * | 2014-12-15 | 2017-12-26 | Univ Emory | phosphoramidates for the treatment of hepatitis b virus |
| KR20190057277A (en) * | 2016-06-24 | 2019-05-28 | 에모리 유니버시티 | Phosphoramidate for the treatment of hepatitis B virus |
| ES2924806T3 (en) | 2016-09-02 | 2022-10-11 | Dicerna Pharmaceuticals Inc | 4'-phosphate analogs and oligonucleotides comprising the same |
| EP3719128A4 (en) | 2017-12-01 | 2021-10-27 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
| WO2019105419A1 (en) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | Nucleic acid, composition and conjugate containing same, preparation method, and use |
| CN111050807B (en) * | 2017-12-01 | 2024-05-28 | 苏州瑞博生物技术股份有限公司 | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application |
| GB201720279D0 (en) * | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| WO2019140365A1 (en) * | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| US11458136B2 (en) | 2018-04-09 | 2022-10-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (en) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | siRNA conjugate and preparation method and application thereof |
| GB201904544D0 (en) * | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| WO2021005912A1 (en) | 2019-07-08 | 2021-01-14 | 日本ポリテック株式会社 | Polyurethane and curable composition |
| KR20220032573A (en) | 2019-07-08 | 2022-03-15 | 닛폰 포리텍쿠 가부시키가이샤 | Cured product, overcoat film, and flexible wiring board |
| CN116437930A (en) * | 2020-10-30 | 2023-07-14 | 上海岸阔医药科技有限公司 | Use of uridine derivatives in the preparation of medicaments |
| WO2022251594A1 (en) * | 2021-05-27 | 2022-12-01 | Antios Therapeutics, Inc. | Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs |
| WO2022256490A2 (en) * | 2021-06-03 | 2022-12-08 | Antios Therapeutics, Inc. | Improved synthesis of phosphoramidates for the treatment of hepatitis b virus |
| WO2022261046A1 (en) * | 2021-06-07 | 2022-12-15 | Antios Therapeutics, Inc. | Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs |
| CN113461760B (en) * | 2021-09-06 | 2021-12-10 | 南京颐媛生物医学研究院有限公司 | 4-thiodeoxythymidine derivative and anti-hepatitis B virus pharmaceutical application thereof |
| CN114524847B (en) * | 2021-09-13 | 2023-06-20 | 南京颐媛生物医学研究院有限公司 | Anti-hepatitis B virus compound, and preparation method and application thereof |
| CN115260263A (en) * | 2022-05-23 | 2022-11-01 | 深圳扬厉医药技术有限公司 | Alkyl sulfur aryl clavudine phosphamide compound and application thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687931A (en) * | 1970-03-19 | 1972-08-29 | Syntex Corp | Halogenated purine and pyrimidine nucleosides and process therefor |
| IS2334B (en) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
| US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| EP1827460A4 (en) | 2004-12-09 | 2012-03-14 | Univ Minnesota | Nucleosides with antiviral and anticancer activity |
| KR101298631B1 (en) | 2005-06-07 | 2013-08-30 | 예일 유니버시티 | methods of treating cancer and other conditions or disease statesusing LFMAU and LDT |
| US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| LT2937350T (en) | 2008-04-23 | 2018-04-10 | Gilead Sciences, Inc. | 1'-substituted carba-nucleoside analogs for antiviral treatment |
| PT2752422T (en) | 2010-03-31 | 2017-11-07 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
| GEP20156313B (en) | 2010-09-22 | 2015-07-10 | Alios Biopharma Inc | Substituted nucleotide analogs |
| US20120142627A1 (en) | 2010-12-06 | 2012-06-07 | Emory University | Monophosphate prodrugs of dapd and analogs thereof |
| EP2734535A4 (en) | 2011-07-19 | 2014-10-22 | Nanjing Molecular Res Inc | 2',3'-DIDEOXY-2'-alpha-FLUORO-2'-beta-C-METHYLNUCLEOSIDES AND PRODRUGS THEREOF |
| WO2013115916A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
| WO2014070771A1 (en) | 2012-10-29 | 2014-05-08 | Rfs Pharma, Llc | Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer |
| WO2014078427A1 (en) * | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| EP2970357A1 (en) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| EP2984097B1 (en) | 2013-04-12 | 2017-03-29 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of hcv |
| US10005779B2 (en) * | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| BR112017012859A2 (en) * | 2014-12-15 | 2017-12-26 | Univ Emory | phosphoramidates for the treatment of hepatitis b virus |
-
2015
- 2015-12-07 BR BR112017012859A patent/BR112017012859A2/en not_active Application Discontinuation
- 2015-12-07 CN CN201580068583.4A patent/CN107428792B/en active Active
- 2015-12-07 AU AU2015363042A patent/AU2015363042B2/en active Active
- 2015-12-07 JP JP2017532167A patent/JP6735751B2/en active Active
- 2015-12-07 EP EP15870694.5A patent/EP3233878A4/en active Pending
- 2015-12-07 SG SG11201704785RA patent/SG11201704785RA/en unknown
- 2015-12-07 IL IL280459A patent/IL280459B2/en unknown
- 2015-12-07 US US15/536,237 patent/US10683319B2/en active Active
- 2015-12-07 WO PCT/US2015/064338 patent/WO2016099982A2/en active Application Filing
- 2015-12-07 CA CA2969372A patent/CA2969372C/en active Active
- 2015-12-07 KR KR1020177019279A patent/KR20170110591A/en not_active Application Discontinuation
- 2015-12-07 SG SG10202013032YA patent/SG10202013032YA/en unknown
-
2017
- 2017-05-31 PH PH12017550022A patent/PH12017550022A1/en unknown
- 2017-06-12 IL IL252842A patent/IL252842B/en active IP Right Grant
- 2017-06-15 ZA ZA2017/04104A patent/ZA201704104B/en unknown
-
2018
- 2018-03-23 HK HK18104080.3A patent/HK1244812A1/en unknown
-
2019
- 2019-06-14 ZA ZA201903906A patent/ZA201903906B/en unknown
-
2020
- 2020-04-29 US US16/861,504 patent/US11447518B2/en active Active
- 2020-07-14 JP JP2020120896A patent/JP7046388B2/en active Active
-
2021
- 2021-05-10 AU AU2021202967A patent/AU2021202967B2/en active Active
- 2021-08-02 US US17/391,586 patent/US11981699B2/en active Active
-
2022
- 2022-03-14 JP JP2022039571A patent/JP2022088451A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| ZA201900156B (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| HK1258795A1 (en) | Methods for treating filoviridae virus infections | |
| EP3393506C0 (en) | Virus purification | |
| HK1231402A1 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections b d | |
| GB201406608D0 (en) | Virus | |
| HK1249046A1 (en) | Methods of treating hepatitis b virus | |
| HK1257272A1 (en) | Means for the treatment of hiv | |
| GB201419572D0 (en) | Virus | |
| SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
| PL3131890T3 (en) | Compounds for treating viral infections | |
| PT3166604T (en) | Substances for the treatment of retroviral infectious diseases | |
| GB201600380D0 (en) | Modified virus | |
| GB201522013D0 (en) | Virus | |
| GB201516936D0 (en) | Virus | |
| GB201507419D0 (en) | Virus | |
| GB201406470D0 (en) | Virus | |
| GB201403582D0 (en) | Virus | |
| GB201408046D0 (en) | Virus preparations |